Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01596140
What this trial is testing

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Who this might be right for
Advanced CancerSolid Tumor
M.D. Anderson Cancer Center 27
Not applicableStudy completedNCT01804140
What this trial is testing

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Who this might be right for
Multiple Myeloma, Neoplasms
Genentech, Inc. 662
Testing effectiveness (Phase 2)Study completedNCT02367859
What this trial is testing

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Who this might be right for
AmeloblastomaBRAF Gene Mutation
Stanford University 1
Testing effectiveness (Phase 2)Looking for participantsNCT05706779
What this trial is testing

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Who this might be right for
Colorectal CancerBRAF V600E Mutation Positive
Federation Francophone de Cancerologie Digestive 30
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775
What this trial is testing

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Who this might be right for
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
M.D. Anderson Cancer Center 58
Early research (Phase 1)Looking for participantsNCT06902376
What this trial is testing

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors
UNC Lineberger Comprehensive Cancer Center 12
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Looking for participantsNCT07110246
What this trial is testing

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Who this might be right for
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco 96
Testing effectiveness (Phase 2)Study completedNCT05510895
What this trial is testing

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Who this might be right for
Colorectal CancerColon CancerBRAF V600E+2 more
AIO-Studien-gGmbH 2
Not applicableLooking for participantsNCT06262919
What this trial is testing

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Who this might be right for
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals 110
Not applicableNo Longer AvailableNCT04489433
What this trial is testing

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02836548
What this trial is testing

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Who this might be right for
MelanomaSkin Neoplasms
The Netherlands Cancer Institute 33
Not applicableStudy completedNCT03663647
What this trial is testing

Advanced Melanoma in Russian Experience

Who this might be right for
Cutaneous Melanoma, Stage IVBRAF V600 Mutation
MelanomaPRO, Russia 382
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Study completedNCT01524978
What this trial is testing

Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Who this might be right for
Multiple Myeloma, Neoplasms
Hoffmann-La Roche 208
Not applicableApproved For MarketingNCT05760586
What this trial is testing

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Who this might be right for
Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Not applicableNot Yet RecruitingNCT05988697
What this trial is testing

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Who this might be right for
NSCLCBRAF V600E MutationAdvanced Cancer+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 36
Testing effectiveness (Phase 2)WithdrawnNCT02115035
What this trial is testing

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Who this might be right for
Multiple Myeloma
University of Arkansas
Next Page